(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Tuscan Holdings Corp. II, Hostess Brands, and X4 Pharmaceuticals.

Rank Financial Asset Price Change Updated (EST)
1 Tuscan Holdings Corp. II (THCAW) 0.07 63% 2022-09-27 03:08:07
2 Hostess Brands (TWNKW) 3.20 41.59% 2022-09-27 05:14:23
3 X4 Pharmaceuticals (XFOR) 1.25 40.18% 2022-09-27 15:46:18
4 VerifyMe (VRMEW) 0.26 30% 2022-09-27 11:11:11
5 Sonnet BioTherapeutics Holdings (SONN) 1.87 16.15% 2022-09-26 19:42:13
6 voxeljet AG (VJET) 3.44 10.14% 2022-09-27 10:17:08
7 AMC (AMC) 7.47 9.44% 2022-09-27 14:52:16
8 Theratechnologies (THTX) 2.33 9.39% 2022-09-27 03:11:08
9 ToughBuilt Industries (TBLT) 2.21 8.87% 2022-09-27 01:10:10
10 MicroVision (MVIS) 3.79 8.6% 2022-09-27 14:58:24

The three biggest losers today are Exicure, Exagen, and Waitr Holdings.

Rank Financial Asset Price Change Updated (EST)
1 Exicure (XCUR) 1.41 -17.06% 2022-09-27 15:14:10
2 Exagen (XGN) 2.69 -9.12% 2022-09-27 15:47:18
3 Waitr Holdings (WTRH) 0.16 -8.94% 2022-09-27 15:06:09
4 Aspen Group (ASPU) 0.34 -8.73% 2022-09-27 13:02:03
5 Uniti Group (UNIT) 6.68 -8.49% 2022-09-27 07:08:09
6 trivago N.V. (TRVG) 1.22 -6.87% 2022-09-27 04:44:15
7 Gyrodyne (GYRO) 9.60 -6.71% 2022-09-27 09:00:28
8 Annaly Capital (NLY) 19.24 -6.63% 2022-09-27 14:48:00
9 U.S. Gold Corp (USAU) 3.60 -6.01% 2022-09-27 14:21:14
10 Strata Skin Sciences (SSKN) 0.79 -5.95% 2022-09-26 21:12:12

Winners today

1. Tuscan Holdings Corp. II (THCAW) – 63%

NASDAQ ended the session with Tuscan Holdings Corp. II jumping 63% to $0.07 on Tuesday while NASDAQ jumped 0.25% to $10,829.50.

Tuscan Holdings Corp. II’s last close was $0.07, 0% under its 52-week high of $0.07.

Tuscan Holdings Corp. II’s Stock Yearly Top and Bottom Value

Tuscan Holdings Corp. II’s stock is valued at $0.07 at 17:32 EST, above its 52-week high of $0.07.

More news about Tuscan Holdings Corp. II.

2. Hostess Brands (TWNKW) – 41.59%

Hostess Brands, Inc. is a US-based packaged food company that develops, produces, markets, distributes, and sells sweet baked goods. The company specializes in snack cakes, donuts and sweet rolls as well as breakfast pastries, snacks pies, and other related products. In-Store Bakery and Sweet Baked Goods are the two main segments of the company. Sweet Baked Goods offers frozen and fresh sweet breads and products, under Dolly Madison and Big Texas brand names, along with store-branded products. Superior on Main-branded baked goods, such as eclairs and madeleines in bakery sections of supermarkets and clubs, are the In-Store Bakery segments. The original name of the company was Gores Holdings, Inc., but it changed its name in November 2016 to Hostess Brands, Inc. Hostess Brands, Inc. is an American company that was established in 1919. Its headquarters are in Lenexa, Kansas.

NASDAQ ended the session with Hostess Brands jumping 41.59% to $3.20 on Tuesday, after five sequential sessions in a row of losses. NASDAQ jumped 0.25% to $10,829.50, after five sequential sessions in a row of losses, on what was a somewhat bullish trend trading session today.

Volume

Today’s last reported volume for Hostess Brands is 29718 which is 70.4% below its average volume of 100427.

Hostess Brands’s last close was $3.20, 20.36% under its 52-week high of $4.02.

Hostess Brands’s Stock Yearly Top and Bottom Value

Hostess Brands’s stock is valued at $3.20 at 17:32 EST, way under its 52-week high of $4.02 and way higher than its 52-week low of $1.12.

Hostess Brands’s Moving Average

Hostess Brands’s worth is below its 50-day moving average of $3.36 and way above its 200-day moving average of $2.53.

More news about Hostess Brands.

3. X4 Pharmaceuticals (XFOR) – 40.18%

X4 Pharmaceuticals, Inc. is a biopharmaceutical company in clinical stage. It focuses on developing, commercializing, and distributing novel therapies for primary immuno-deficiencies, as well as cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and WaldenstrAPm macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company also develops X4P002 to treat glioblastoma multifida; and X4P003 for primary immuno-deficiencies. Abbisko Therapeutics Co. Ltd. has granted it a license to manufacture and market mavorixafor, in conjunction with other checkpoint inhibitors, or agents for oncology indications. Arsanis, Inc. was the company’s former name. In March 2019, X4 Pharmaceuticals, Inc. became X4 Pharmaceuticals, Inc. X4 Pharmaceuticals, Inc. is a Massachusetts-based company that was established in 2014.

NASDAQ ended the session with X4 Pharmaceuticals rising 40.18% to $1.25 on Tuesday while NASDAQ rose 0.25% to $10,829.50.

Volume

Today’s last reported volume for X4 Pharmaceuticals is 9377410 which is 1963.54% above its average volume of 454434.

X4 Pharmaceuticals’s last close was $0.89, 85.57% below its 52-week high of $6.18.

The company’s growth estimates for the present quarter and the next is 13.5% and 43.4%, respectively.

X4 Pharmaceuticals’s Stock Yearly Top and Bottom Value

X4 Pharmaceuticals’s stock is valued at $1.25 at 17:32 EST, way below its 52-week high of $6.18 and way above its 52-week low of $0.86.

X4 Pharmaceuticals’s Moving Average

X4 Pharmaceuticals’s value is higher than its 50-day moving average of $1.14 and way below its 200-day moving average of $1.52.

More news about X4 Pharmaceuticals.

4. VerifyMe (VRMEW) – 30%

NASDAQ ended the session with VerifyMe rising 30% to $0.26 on Tuesday, after five successive sessions in a row of losses. NASDAQ rose 0.25% to $10,829.50, after five sequential sessions in a row of losses, on what was a somewhat up trend exchanging session today.

VerifyMe’s last close was $0.41, 57.69% above its 52-week high of $0.26.

VerifyMe’s Stock Yearly Top and Bottom Value

VerifyMe’s stock is valued at $0.26 at 17:32 EST, way below its 52-week low of $0.20.

More news about VerifyMe.

5. Sonnet BioTherapeutics Holdings (SONN) – 16.15%

Sonnet BioTherapeutics Holdings, Inc., is a biotechnology company that focuses on clinical stages in cancer. It develops platforms for biologic medicines with single- or bispecific actions. Fully human albumin binding technology is developed by the company. It uses human single-chain antibodies fragments that attach to human serum albumin and then transport it to its target tissues. Its leading candidate is SON-1010 which is a humanized version of interleukin 12, for treatment of head and neck and non-small cell lung carcinoma. It is currently developing SON080, a humanized version of interleukin 6, for treatment of chemotherapy-induced peripheral nerve disease and diabetic peripheral neuralgia. New Life Therapeutics PTE LTD. has granted it a license to commercialize and develop pharmaceutical products containing specific human interleukin 6 Sonnet BioTherapeutics Holdings, Inc., is located in Princeton, New Jersey.

NASDAQ ended the session with Sonnet BioTherapeutics Holdings rising 16.15% to $1.87 on Tuesday, following the last session’s upward trend. NASDAQ jumped 0.25% to $10,829.50, after five consecutive sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Volume

Today’s last reported volume for Sonnet BioTherapeutics Holdings is 564948 which is 76.96% above its average volume of 319240.

Sonnet BioTherapeutics Holdings’s last close was $1.87, 81.7% below its 52-week high of $10.22.

Sonnet BioTherapeutics Holdings’s Stock Yearly Top and Bottom Value

Sonnet BioTherapeutics Holdings’s stock is valued at $1.87 at 17:32 EST, way under its 52-week high of $10.22 and way above its 52-week low of $1.23.

Sonnet BioTherapeutics Holdings’s Moving Average

Sonnet BioTherapeutics Holdings’s value is way below its 50-day moving average of $3.38 and way below its 200-day moving average of $4.34.

More news about Sonnet BioTherapeutics Holdings.

6. voxeljet AG (VJET) – 10.14%

voxeljet AG offers three-dimensional (3D), printers as well as on-demand part services for industrial and commercial customers throughout Europe, Africa, Asia Pacific and the Americas. The company operates two divisions, Systems and Services. Systems is responsible for the development, manufacturing, and sale of 3D printers. The segment offers spare parts, consumables such as particulate material and chemical binding agents. Services provides services such as printing on-demand parts and creating molds, cores and parts using 3D computer-aided designing at its service centre. Through its sales team and network of agents, it serves the automotive, aerospace and engineering markets as well as foundries, suppliers, universities, research institutes, and end-users in engineering and art. The original name of the company was Voxeljet Technology GmbH. In January 2004, it changed its name back to voxeljet GmbH. It is headquartered at Friedberg in Germany.

NASDAQ ended the session with voxeljet AG rising 10.14% to $3.44 on Tuesday while NASDAQ jumped 0.25% to $10,829.50.

Volume

Today’s last reported volume for voxeljet AG is 2790 which is 90.84% below its average volume of 30479.

voxeljet AG’s last close was $3.12, 68.8% under its 52-week high of $10.00.

voxeljet AG’s Sales

voxeljet AG’s sales growth is 10.7% for the present quarter and a decline by 17.4% for the next. The company’s growth estimates for the present quarter and the next is a negative 207.1% and a negative 260%, respectively.

voxeljet AG’s Revenue

Year-on-year quarterly revenue growth grew by 35.4%, now sitting on 27.15M for the twelve trailing months.

voxeljet AG’s Stock Yearly Top and Bottom Value

voxeljet AG’s stock is valued at $3.44 at 17:32 EST, way under its 52-week high of $10.00 and way higher than its 52-week low of $3.11.

voxeljet AG’s Moving Average

voxeljet AG’s value is way below its 50-day moving average of $4.67 and way under its 200-day moving average of $4.80.

More news about voxeljet AG.

7. AMC (AMC) – 9.44%

Through its subsidiaries, AMC Entertainment Holdings, Inc. engages in theatrical exhibitions. It owns or operates theatres in Europe and the United States. It operated approximately 950 theaters and 10600 screens as of March 1, 2022. It was established in 1920. The headquarters are in Leawood in Kansas.

NYSE ended the session with AMC rising 9.44% to $7.47 on Tuesday, after two consecutive sessions in a row of losses. NYSE fell 0.28% to $13,541.76, after five consecutive sessions in a row of losses, on what was a somewhat down trend exchanging session today.

BBBY stock prediction: Bed bath and Beyond slips in AMC’s sell-off, leading to lower meme stocks
Retail traders were heading to the hills when AMC Entertainment (AMC), announced a possible stock sale.

Volume

Today’s last reported volume for AMC is 31765700 which is 25.94% below its average volume of 42895000.

AMC’s last close was $6.83, 85.14% under its 52-week high of $45.95.

The company’s growth estimates for the ongoing quarter and the next is 73.2% and 52.3%, respectively.

AMC’s Revenue

Year-on-year quarterly revenue growth grew by 429.8%, now sitting on 3.17B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

AMC’s stock is considered to be overbought (>=80).

AMC’s Stock Yearly Top and Bottom Value

AMC’s stock is valued at $7.47 at 17:33 EST, below its 52-week low of $7.89.

AMC’s Moving Average

AMC’s value is way below its 50-day moving average of $14.85 and way under its 200-day moving average of $17.36.

Previous days news about AMC

  • AMC stock forecast: AMC entertainment rises as meme stocks outperform broader markets. According to FXStreet on Monday, 26 September, "Meme stocks bucked the market trend on Friday as AMC and GameStop (NYSE:GME) both rose higher to close the week. ", "Unfortunately for AMC shareholders, the APE (NYSE:APE) preferred shares hit yet another all-time low and closed the week at a price of just $3.58. "
  • Apes sink toward new low after AMC discloses deal for sale of up to $1.4 billion worth of shares. According to MarketWatch on Monday, 26 September, "Shares of AMC Preferred Equity Units , disclosed a distribution agreement to sell up to 425.0 million APEs. ", "Over the same time, AMC shares have sunk 26.3% and the S&P 500 has dropped 10.6%."
  • ‘apes’ react to disclosure of AMC plan to sell up to 425 million new shares. According to MarketWatch on Monday, 26 September, "Shares of AMC Preferred Equity Units , disclosed a distribution agreement to sell up to 425.0 million APEs. ", "Over the same time, AMC shares have sunk 26.3% and the S&P 500 has dropped 10.6%."

More news about AMC.

8. Theratechnologies (THTX) – 9.39%

Theratechnologies Inc. is a biopharmaceutical firm that focuses on developing and commercializing therapies for unmet medical needs across the United States and Europe. EGRIFTA SV and EGRIFTA SV are available for patients suffering from lipodystrophy caused by HIV. Trogarzo is an injection that contains ibalizumab to treat multidrug-resistant HIV-1 patients. F8 Formulation is a treatment for lipodystrophy among HIV-infected people; TH1902, which are in Phase 1/Part A clinical trial for triple negative breast cancer treatment; and TH1904 to treat ovarian cancer. Montreal is the headquarters of this company, which was founded in 1993.

NASDAQ ended the session with Theratechnologies rising 9.39% to $2.33 on Tuesday while NASDAQ rose 0.25% to $10,829.50.

Volume

Today’s last reported volume for Theratechnologies is 355171 which is 604.43% above its average volume of 50419.

Theratechnologies’s last close was $2.33, 40.56% below its 52-week high of $3.92.

The company’s growth estimates for the current quarter and the next is a negative 20% and a negative 10%, respectively.

Theratechnologies’s Revenue

Year-on-year quarterly revenue growth grew by 8.3%, now sitting on 74.43M for the twelve trailing months.

Theratechnologies’s Stock Yearly Top and Bottom Value

Theratechnologies’s stock is valued at $2.33 at 17:33 EST, way below its 52-week high of $3.92 and way above its 52-week low of $1.89.

Theratechnologies’s Moving Average

Theratechnologies’s value is higher than its 50-day moving average of $2.18 and under its 200-day moving average of $2.55.

More news about Theratechnologies.

9. ToughBuilt Industries (TBLT) – 8.87%

ToughBuilt Industries, Inc. develops, produces, distributes, and markets home and building improvement products in the United States as well as internationally. It offers tool pouches, tool rigs, tool belts and accessories, tools bags, totes, various storage solutions, and office organizers/bags for laptop/tablet/cellphones, etc. Also available are kneepads. It also offers sawhorses and miter saws as well as table and roller saws and roll stands. The company sells its products through TOUGHBUILT outlets and professional outlets. It also direct markets to contractors and wholesale/wholesale shops. It was previously known as Phalanx, Inc., but changed its name in December 2015 to ToughBuilt Industries, Inc. ToughBuilt Industries, Inc. is an American company that was founded in 2012. Its headquarters are located in Lake Forest, California.

NASDAQ ended the session with ToughBuilt Industries jumping 8.87% to $2.21 on Tuesday while NASDAQ jumped 0.25% to $10,829.50.

Volume

Today’s last reported volume for ToughBuilt Industries is 2528040 which is 78.37% below its average volume of 11692700.

ToughBuilt Industries’s last close was $2.21, 97.62% below its 52-week high of $92.85.

ToughBuilt Industries’s Revenue

Year-on-year quarterly revenue growth grew by 12.8%, now sitting on 77M for the twelve trailing months.

ToughBuilt Industries’s Stock Yearly Top and Bottom Value

ToughBuilt Industries’s stock is valued at $2.21 at 17:33 EST, way below its 52-week high of $92.85 and way above its 52-week low of $1.34.

ToughBuilt Industries’s Moving Average

ToughBuilt Industries’s worth is way below its 50-day moving average of $4.35 and way under its 200-day moving average of $20.48.

More news about ToughBuilt Industries.

10. MicroVision (MVIS) – 8.6%

MicroVision, Inc. makes lidar sensors for autonomous driving and automotive safety. Micro-electrical mechanical system, laser diodes and opto-mechanics are the key components of its laser beam scanning technology. Micro-display designs and concepts are also developed by the company for AR headsets. PicoP is a scanner technology that produces a uniform, full-color, high-contrast image across the entire area-of-view using a tiny and lightweight module. The company also develops a 1st-generation long range lidar. It sells its products mostly to original equipment and design makers. MicroVision, Inc., was established in 1993. It is located in Redmond, Washington.

NASDAQ ended the session with MicroVision jumping 8.6% to $3.79 on Tuesday, after four consecutive sessions in a row of losses. NASDAQ rose 0.25% to $10,829.50, after five consecutive sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Volume

Today’s last reported volume for MicroVision is 1843990 which is 24.22% below its average volume of 2433530.

MicroVision’s last close was $3.49, 72.82% under its 52-week high of $12.84.

MicroVision’s Sales

MicroVision’s sales growth is 53.2% for the present quarter and 151.3% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 50% and a negative 12.5%, respectively.

MicroVision’s Revenue

Year-on-year quarterly revenue growth declined by 57.9%, now sitting on 1.94M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

MicroVision’s stock is considered to be overbought (>=80).

MicroVision’s Stock Yearly Top and Bottom Value

MicroVision’s stock is valued at $3.79 at 17:33 EST, way below its 52-week high of $12.84 and way higher than its 52-week low of $2.50.

MicroVision’s Moving Average

MicroVision’s value is way below its 50-day moving average of $4.91 and way under its 200-day moving average of $4.31.

More news about MicroVision.

Losers Today

1. Exicure (XCUR) – -17.06%

Exicure, Inc. is a biotechnology company in clinical stage. It develops therapies for neurology, immunooncology, and inflammatory disorders using its proprietary Spherical Nucleic Acid (SNA). It has AST-008, a drug candidate, in Phase 1b/2 clinical trials with patients with advanced solid tumours. The company also has XCURFXN (a SNAA-based therapeutic agent) in preclinical studies for Friedreich’s Ataxia. XCUR17 is an SNA which targets messenger RNAs (mRNA) that encode interleukin-17 receptor alpha. The company has an option, collaboration, and license agreement for SNA-based treatment for hair loss disorders with Allergan Pharmaceuticals International Limited. It also has a license and development agreement for DERMELIX, LLC, to help develop, commercialize, and research its technology to treat netherton syndrome. It was established in Chicago, Illinois in 2011.

NASDAQ ended the session with Exicure dropping 17.06% to $1.41 on Tuesday while NASDAQ jumped 0.25% to $10,829.50.

Volume

Today’s last reported volume for Exicure is 107487 which is 77.68% below its average volume of 481733.

Exicure’s last close was $1.70, 95.64% under its 52-week high of $39.00.

Exicure’s Sales

Exicure’s sales growth is 6.1% for the current quarter and 84.1% for the next. The company’s growth estimates for the ongoing quarter and the next is 88.9% and 95.8%, respectively.

Exicure’s Revenue

Year-on-year quarterly revenue growth grew by 3027.8%, now sitting on 3.48M for the twelve trailing months.

Exicure’s Stock Yearly Top and Bottom Value

Exicure’s stock is valued at $1.41 at 17:34 EST, way below its 52-week high of $39.00 and higher than its 52-week low of $1.39.

Exicure’s Moving Average

Exicure’s value is way under its 50-day moving average of $1.89 and way under its 200-day moving average of $4.40.

More news about Exicure.

2. Exagen (XGN) – -9.12%

Exagen Inc. designs and markets various products based upon its Cell-Bound Complement Activation Products Technology under the AVISE trademark in the United States. This technology allows rheumatologists and other healthcare professionals to improve patient care by diagnosing, prognosis and monitoring complex autoimmune or autoimmune-related diseases such as systemic lupus erythematosus and rheumatoidarthritis (RA). The company’s leading testing product, AVISE CTD, allows for differential diagnosis in patients with signs that are indicative of connective tissue diseases (CTDs), and related disorders with overlapping symptoms. AVISE Lupus, which measures activation in the complement system through quantifying B-cell and erythrocyte bound levels of C4d in patients’ blood; and AVISE APS. This panel includes eight autoantibody test panels that assist in diagnosing and managing APS. It also offers AVISE SLE PROGNOSIS, a ten biomarker panel autoantibodies that can be used to assess the possibility of complications affecting the brain, kidney and cardiovascular systems; AVISE anti-CarP, which identifies RA sufferers with serious disease that requires aggressive treatment such as anti-TNF biologics; AVISE PC4d, which measures platelet-bound C4d. The company also offers AVISE MTX and AVISE MTX blood tests that measure levels of MTXPG. AVISE HCQ is a test to objectively assess the levels of hydroxychloroquine in blood. Exagen Diagnostics, Inc. was the company’s previous name. In January 2019, Exagen Inc. became Exagen Inc. Exagen Inc. is located in Vista, California. It was founded in 2002.

NASDAQ ended the session with Exagen dropping 9.12% to $2.69 on Tuesday while NASDAQ rose 0.25% to $10,829.50.

Volume

Today’s last reported volume for Exagen is 15897 which is 38.89% below its average volume of 26017.

Exagen’s last close was $3.10, 79.12% below its 52-week high of $14.85.

The company’s growth estimates for the present quarter and the next is a negative 50% and a negative 16.7%, respectively.

Exagen’s Revenue

Year-on-year quarterly revenue growth declined by 1.8%, now sitting on 48.11M for the twelve trailing months.

Exagen’s Stock Yearly Top and Bottom Value

Exagen’s stock is valued at $2.69 at 17:34 EST, way below its 52-week high of $14.85 and above its 52-week low of $2.65.

Exagen’s Moving Average

Exagen’s value is way under its 50-day moving average of $5.56 and way below its 200-day moving average of $7.06.

More news about Exagen.

3. Waitr Holdings (WTRH) – -8.94%

Waitr Holdings Inc. offers online ordering and delivery in the United States. The Waitr Platform, and Bite Squad Platform allow diners to order food and drinks from their restaurant partners and have them delivered by a network. The company has approximately 18,000 partners in over 640 cities as of December 31, 2019. Lafayette, Louisiana is the headquarters of this company.

NASDAQ ended the session with Waitr Holdings dropping 8.94% to $0.16 on Tuesday while NASDAQ rose 0.25% to $10,829.50.

Volume

Today’s last reported volume for Waitr Holdings is 3110140 which is 72.17% below its average volume of 11177500.

Waitr Holdings’s last close was $0.18, 92.28% under its 52-week high of $2.28.

Waitr Holdings’s Revenue

Year-on-year quarterly revenue growth declined by 36.6%, now sitting on 148.31M for the twelve trailing months.

Waitr Holdings’s Stock Yearly Top and Bottom Value

Waitr Holdings’s stock is valued at $0.16 at 17:34 EST, way under its 52-week high of $2.28 and way above its 52-week low of $0.14.

Waitr Holdings’s Moving Average

Waitr Holdings’s value is way below its 50-day moving average of $0.28 and way below its 200-day moving average of $0.38.

More news about Waitr Holdings.

4. Aspen Group (ASPU) – -8.73%

Aspen Group, Inc., a technology-based education company, offers online higher education in the United States. It offers certificates, bachelor’s and master’s degree programs, along with programs that can lead to doctoral degrees in business, technology and arts. It had 13 334 students who were pursuing degrees as of April 30, 2022. Aspen Group, Inc., was established in 1987. It is located in New York, New York.

NASDAQ ended the session with Aspen Group dropping 8.73% to $0.34 on Tuesday while NASDAQ jumped 0.25% to $10,829.50.

Volume

Today’s last reported volume for Aspen Group is 133193 which is 79.89% above its average volume of 74039.

Aspen Group’s last close was $0.38, 93.78% below its 52-week high of $6.04.

The company’s growth estimates for the current quarter and the next is a negative 266.7% and a negative 12.5%, respectively.

Aspen Group’s Revenue

Year-on-year quarterly revenue growth grew by 1.7%, now sitting on 76.69M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Aspen Group’s stock is considered to be overbought (>=80).

Aspen Group’s Stock Yearly Top and Bottom Value

Aspen Group’s stock is valued at $0.34 at 17:34 EST, way below its 52-week low of $0.46.

Aspen Group’s Moving Average

Aspen Group’s worth is way under its 50-day moving average of $0.95 and way under its 200-day moving average of $1.36.

More news about Aspen Group.

5. Uniti Group (UNIT) – -8.49%

Uniti is an internal managed real estate investment trust that focuses on the acquisition and construction mission-critical communications infrastructure. It is also a major provider of solutions in wireless infrastructure for the communication industry. Uniti has 6.5 million miles of fiber and other communication real estate in the United States as of 30 June 2020.

NASDAQ ended the session with Uniti Group sliding 8.49% to $6.68 on Tuesday, after five sequential sessions in a row of losses. NASDAQ rose 0.25% to $10,829.50, after five sequential sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Volume

Today’s last reported volume for Uniti Group is 2869140 which is 116.33% above its average volume of 1326270.

Uniti Group’s last close was $6.68, 54.25% under its 52-week high of $14.60.

Uniti Group’s Sales

Uniti Group’s sales growth is 6.2% for the ongoing quarter and a decline by 2.3% for the next. The company’s growth estimates for the current quarter and the next is 5.9% and 20%, respectively.

Uniti Group’s Revenue

Year-on-year quarterly revenue growth grew by 5.9%, now sitting on 1.12B for the twelve trailing months.

Uniti Group’s Stock Yearly Top and Bottom Value

Uniti Group’s stock is valued at $6.68 at 17:34 EST, way below its 52-week high of $14.60 and above its 52-week low of $6.66.

Uniti Group’s Moving Average

Uniti Group’s worth is way under its 50-day moving average of $9.46 and way below its 200-day moving average of $11.40.

More news about Uniti Group.

6. trivago N.V. (TRVG) – -6.87%

trivago N.V. and its subsidiaries operate a global hotel and accommodation search engine in the United States of America, Germany, Britain, and elsewhere. The online search engine allows you to find hotels and accommodations through independent and chain hotels, online travel agencies and hotel chains. Access to the company’s platform is available through 53 websites and applications in local languages. The company’s hotel search platform provided access to more than 5.0 million hotels worldwide as of December 31, 2021. It was founded in 2005, and its headquarters are in Dusseldorf in Germany. trivago N.V., a subsidiary Expedia Lodging Partner Services Sarl.

NASDAQ ended the session with trivago N.V. falling 6.87% to $1.22 on Tuesday while NASDAQ jumped 0.25% to $10,829.50.

Volume

Today’s last reported volume for trivago N.V. is 756649 which is 132.05% above its average volume of 326063.

trivago N.V.’s last close was $1.22, 61.88% under its 52-week high of $3.20.

trivago N.V.’s Sales

trivago N.V.’s sales growth is 34.3% for the present quarter and 25.8% for the next.

trivago N.V.’s Revenue

Year-on-year quarterly revenue growth grew by 165.9%, now sitting on 424.88M for the twelve trailing months.

trivago N.V.’s Stock Yearly Top and Bottom Value

trivago N.V.’s stock is valued at $1.22 at 17:34 EST, way under its 52-week high of $3.20 and above its 52-week low of $1.21.

trivago N.V.’s Moving Average

trivago N.V.’s worth is way below its 50-day moving average of $1.53 and way under its 200-day moving average of $1.90.

More news about trivago N.V..

7. Gyrodyne (GYRO) – -6.71%

Gyrodyne, LLC. Gyrodyne, LLC. Owns, leases, and manages various commercial properties. It is known for its customer-oriented approach to property management and ownership. Gyrodyne is now a multi-faceted East Coast firm with a strong focus on medical offices. It started as a small player in Long Island.

NASDAQ ended the session with Gyrodyne falling 6.71% to $9.60 on Tuesday, following the last session’s downward trend. NASDAQ rose 0.25% to $10,829.50, after five sequential sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Volume

Today’s last reported volume for Gyrodyne is 6634 which is 831.74% above its average volume of 712.

Gyrodyne’s last close was $9.80, 34.1% under its 52-week high of $14.87.

Gyrodyne’s Revenue

Year-on-year quarterly revenue growth declined by 1.8%, now sitting on 2.74M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Gyrodyne’s stock is considered to be oversold (<=20).

Gyrodyne’s Stock Yearly Top and Bottom Value

Gyrodyne’s stock is valued at $9.60 at 17:34 EST, way below its 52-week high of $14.87 and higher than its 52-week low of $9.55.

Gyrodyne’s Moving Average

Gyrodyne’s worth is way under its 50-day moving average of $11.24 and way below its 200-day moving average of $12.06.

More news about Gyrodyne.

8. Annaly Capital (NLY) – -6.63%

Annaly Capital Management, Inc. is a multi-faceted capital manager that specializes in corporate and mortgage financing. It invests in mortgage servicing rights, agency mortgage-backed security, commercial mortgage-backed Securities, non-Agency residential assets, residential loans, credit risk transfer securities and corporate debts. The company has chosen to be treated as a real-estate investment trust (REIT) tax. It is exempt from federal income taxes if it pays its shareholders its taxable income as a REIT. It was established in New York in 1996.

NYSE ended the session with Annaly Capital dropping 6.63% to $19.24 on Tuesday while NYSE slid 0.28% to $13,541.76.

Volume

Today’s last reported volume for Annaly Capital is 18790500 which is 115.98% above its average volume of 8699840.

Annaly Capital’s last close was $20.60, 42.39% under its 52-week high of $35.76.

Annaly Capital’s Sales

Annaly Capital’s sales growth is 19.3% for the ongoing quarter and 9.6% for the next. The company’s growth estimates for the current quarter and the next is a negative 17.9% and a negative 21.4%, respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Annaly Capital’s stock is considered to be overbought (>=80).

Annaly Capital’s Stock Yearly Top and Bottom Value

Annaly Capital’s stock is valued at $19.24 at 17:34 EST, way under its 52-week high of $35.76 and way higher than its 52-week low of $5.59.

Annaly Capital’s Moving Average

Annaly Capital’s value is way below its 50-day moving average of $25.99 and way below its 200-day moving average of $27.39.

More news about Annaly Capital.

9. U.S. Gold Corp (USAU) – -6.01%

U.S. Gold Corp. is a precious metals and gold exploration company. The company explores for zinc, copper, silver and gold deposits. It holds an interest in the CK Gold mining project in southeast Wyoming’s Silver Crown. The company also owns interests in Maggie Creek and Keystone exploration properties, which are located on the Cortez Trends and Carlin Trends in Eureka County in Nevada. It also has an interest in Idaho’s Challis-Gold project. Elko is the company’s headquarters. Copper King, LLC was the former parent company of U.S. Gold Corp.

NASDAQ ended the session with U.S. Gold Corp dropping 6.01% to $3.60 on Tuesday while NASDAQ rose 0.25% to $10,829.50.

Volume

Today’s last reported volume for U.S. Gold Corp is 8347 which is 62.6% below its average volume of 22322.

U.S. Gold Corp’s last close was $3.70, 68.19% below its 52-week high of $11.63.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

U.S. Gold Corp’s stock is considered to be overbought (>=80).

U.S. Gold Corp’s Stock Yearly Top and Bottom Value

U.S. Gold Corp’s stock is valued at $3.60 at 17:35 EST, way under its 52-week high of $11.63 and higher than its 52-week low of $3.50.

U.S. Gold Corp’s Moving Average

U.S. Gold Corp’s worth is under its 50-day moving average of $3.93 and way under its 200-day moving average of $6.00.

More news about U.S. Gold Corp.

10. Strata Skin Sciences (SSKN) – -5.95%

STRATA Skin Sciences, Inc. is a medical technology company that develops, markets, and sells products to treat dermatologic conditions. It operates in America, Europe, Asia, Australia, South Africa, Central and South America, Europe, Asia, Australia, the Middle East, Asia, Australia, South Africa, South Africa, South Africa, Central and South America. It operates two divisions: Dermatology Procedures Equipment and Dermatology Recurring Procedures. The company’s products include XTRAC, Pharos, VTRAC lamps systems and TheraClear treatment system that can be used to treat psoriasis and other skin conditions such as vitiligo and acne. It distributes its products worldwide through distributors and directly to doctors in the United States. The original name of the company was MELA Sciences, Inc. It changed its name to STRATA Skin Sciences, Inc. on January 2016. STRATA Skin Sciences, Inc. is a Pennsylvania-based company that was founded in 1989.

NASDAQ ended the session with Strata Skin Sciences sliding 5.95% to $0.79 on Tuesday, after three consecutive sessions in a row of losses. NASDAQ jumped 0.25% to $10,829.50, after five successive sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Volume

Today’s last reported volume for Strata Skin Sciences is 57311 which is 35.76% below its average volume of 89217.

Strata Skin Sciences’s last close was $0.79, 59.49% under its 52-week high of $1.95.

Strata Skin Sciences’s Sales

Strata Skin Sciences’s sales growth is 9.6% for the current quarter and 4.6% for the next. The company’s growth estimates for the present quarter and the next is a negative 200% and a negative 100%, respectively.

Strata Skin Sciences’s Revenue

Year-on-year quarterly revenue growth grew by 23.3%, now sitting on 32.91M for the twelve trailing months.

Strata Skin Sciences’s Stock Yearly Top and Bottom Value

Strata Skin Sciences’s stock is valued at $0.79 at 17:35 EST, way below its 52-week high of $1.95 and above its 52-week low of $0.76.

Strata Skin Sciences’s Moving Average

Strata Skin Sciences’s value is way under its 50-day moving average of $1.02 and way below its 200-day moving average of $1.25.

More news about Strata Skin Sciences.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here